We are working on the development of biosimilars in close collaboration with Chemical Bio Research, an operating company of Yoshindo Holdings.

Yoshindo founded YL Biologics together with Lupin in 2014 with the aim of developing and manufacturing biosimilars. The first drug we have chosen to develop a biosimilar for is Enbrel which is used to treat rheumatoid arthritis. This was implemented via Lupin Limited and has been succeeded in developing globally and Yoshindo is a manufacturing and sales folder for the product in Japan.